Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/25831 |
Resumo: | Andrade, Bruno Bezerril. “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”. 1Immunobiology Section, Laboratory of Parasitic Diseases (LPD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA. 2Department of Immunology, Biomedical Sciences Institutes, University of Sao Paulo, 05508-900 Sao Paulo, Brazil. 3T Lymphocyte Biology Unit, LPD, NIAID, NIH, Bethesda, Maryland 20892, USA. 4Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, NIAID, NIH, Bethesda, Maryland 20892, USA. 5Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA. 6Henan Chest Hospital, 450003 Zhengzhou, China. 7NIH, International Center for Excellence in Research, 600 031 Chennai, India. 8National Institute for Research in Tuberculosis (NIRT), 600 031 Chennai, India. 9Sino-US International Research Center for Tuberculosis, and Henan Public Health Center, 450003 Zhengzhou, China. 10Helminth Immunology Section, LPD, NIAID, NIH, Bethesda, Maryland 20892, USA. 11Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland 20892, USA. 12Oncovir Inc., Washington, Washington DC 20008, USA. |
id |
CRUZ_e10ff996cc394ecb881ebb4c7b6b3d9a |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/25831 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Barber, Katrin D. MayerAndrade, Bruno de BezerrilOland, Sandra DAmaral, Eduardo PinheiroBarber, Daniel LGonzales, JacquelineDerrick, Steven CShi, RuiruKumar, Nathella PavanWei, WangYuan, XingZhang, GuolongCai, YingBabu, SubashCatalfamo, MartaSalazar, Andres MVia, Laura EBarry, Clifton ESher, Alan2018-04-12T18:19:08Z2018-04-12T18:19:08Z2014BARBER, K. D. M. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature, 20140028-0836https://www.arca.fiocruz.br/handle/icict/2583110.1038/nature13489Andrade, Bruno Bezerril. “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”. 1Immunobiology Section, Laboratory of Parasitic Diseases (LPD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA. 2Department of Immunology, Biomedical Sciences Institutes, University of Sao Paulo, 05508-900 Sao Paulo, Brazil. 3T Lymphocyte Biology Unit, LPD, NIAID, NIH, Bethesda, Maryland 20892, USA. 4Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, NIAID, NIH, Bethesda, Maryland 20892, USA. 5Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA. 6Henan Chest Hospital, 450003 Zhengzhou, China. 7NIH, International Center for Excellence in Research, 600 031 Chennai, India. 8National Institute for Research in Tuberculosis (NIRT), 600 031 Chennai, India. 9Sino-US International Research Center for Tuberculosis, and Henan Public Health Center, 450003 Zhengzhou, China. 10Helminth Immunology Section, LPD, NIAID, NIH, Bethesda, Maryland 20892, USA. 11Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland 20892, USA. 12Oncovir Inc., Washington, Washington DC 20008, USA.NIAID Intramural Research program and a Concept Acceleration Program-AwardMúltipla – ver em NotasTuberculosis remains second only to HIV/AIDS as the leading cause of mortality worldwide due to a single infectious agent. Despite chemotherapy, the global tuberculosis epidemic has intensified because of HIV co-infection, the lack of an effective vaccine and the emergence of multi-drug-resistant bacteria. Alternative host-directed strategies could be exploited to improve treatment efficacy and outcome, contain drug-resistant strains and reduce disease severity and mortality. The innate inflammatory response elicited by Mycobacterium tuberculosis (Mtb) represents a logical host target. Here we demonstrate that interleukin-1 (IL-1) confers host resistance through the induction of eicosanoids that limit excessive type I interferon (IFN) production and foster bacterial containment. We further show that, in infected mice and patients, reduced IL-1 responses and/or excessive type I IFN induction are linked to an eicosanoid imbalance associated with disease exacerbation. Host-directed immunotherapy with clinically approved drugs that augment prostaglandin E2 levels in these settings prevented acute mortality of Mtb-infected mice. Thus, IL-1 and type I IFNs represent two major counter-regulatory classes of inflammatory cytokines that control the outcome of Mtb infection and are functionally linked via eicosanoids. Our findings establish proof of concept for host-directed treatment strategies that manipulate the host eicosanoid network and represent feasible alternatives to conventional chemotherapy.engNature Publishing GroupTuberculose PulmonarMycobacterium tuberculosisInterleucina-1VacinaInfecçãoTuberculosis PulmonaryMycobacterium tuberculosisInterleukin-1VaccineInfectionHost-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalkinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/25831/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALBarber KDM Host-directed....pdfBarber KDM Host-directed....pdfapplication/pdf1524781https://www.arca.fiocruz.br/bitstream/icict/25831/2/Barber%20KDM%20Host-directed....pdfeb635d7b2a92a1081db2fea05b1a95daMD52TEXTBarber KDM Host-directed....pdf.txtBarber KDM Host-directed....pdf.txtExtracted texttext/plain82281https://www.arca.fiocruz.br/bitstream/icict/25831/3/Barber%20KDM%20Host-directed....pdf.txt19d7bad923c15f3a5dad7ab6af09e83bMD53icict/258312023-03-15 14:34:07.568oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:07Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.pt_BR.fl_str_mv |
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk |
title |
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk |
spellingShingle |
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk Barber, Katrin D. Mayer Tuberculose Pulmonar Mycobacterium tuberculosis Interleucina-1 Vacina Infecção Tuberculosis Pulmonary Mycobacterium tuberculosis Interleukin-1 Vaccine Infection |
title_short |
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk |
title_full |
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk |
title_fullStr |
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk |
title_full_unstemmed |
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk |
title_sort |
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk |
author |
Barber, Katrin D. Mayer |
author_facet |
Barber, Katrin D. Mayer Andrade, Bruno de Bezerril Oland, Sandra D Amaral, Eduardo Pinheiro Barber, Daniel L Gonzales, Jacqueline Derrick, Steven C Shi, Ruiru Kumar, Nathella Pavan Wei, Wang Yuan, Xing Zhang, Guolong Cai, Ying Babu, Subash Catalfamo, Marta Salazar, Andres M Via, Laura E Barry, Clifton E Sher, Alan |
author_role |
author |
author2 |
Andrade, Bruno de Bezerril Oland, Sandra D Amaral, Eduardo Pinheiro Barber, Daniel L Gonzales, Jacqueline Derrick, Steven C Shi, Ruiru Kumar, Nathella Pavan Wei, Wang Yuan, Xing Zhang, Guolong Cai, Ying Babu, Subash Catalfamo, Marta Salazar, Andres M Via, Laura E Barry, Clifton E Sher, Alan |
author2_role |
author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Barber, Katrin D. Mayer Andrade, Bruno de Bezerril Oland, Sandra D Amaral, Eduardo Pinheiro Barber, Daniel L Gonzales, Jacqueline Derrick, Steven C Shi, Ruiru Kumar, Nathella Pavan Wei, Wang Yuan, Xing Zhang, Guolong Cai, Ying Babu, Subash Catalfamo, Marta Salazar, Andres M Via, Laura E Barry, Clifton E Sher, Alan |
dc.subject.other.pt_BR.fl_str_mv |
Tuberculose Pulmonar Mycobacterium tuberculosis Interleucina-1 Vacina Infecção |
topic |
Tuberculose Pulmonar Mycobacterium tuberculosis Interleucina-1 Vacina Infecção Tuberculosis Pulmonary Mycobacterium tuberculosis Interleukin-1 Vaccine Infection |
dc.subject.en.pt_BR.fl_str_mv |
Tuberculosis Pulmonary Mycobacterium tuberculosis Interleukin-1 Vaccine Infection |
description |
Andrade, Bruno Bezerril. “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”. 1Immunobiology Section, Laboratory of Parasitic Diseases (LPD), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA. 2Department of Immunology, Biomedical Sciences Institutes, University of Sao Paulo, 05508-900 Sao Paulo, Brazil. 3T Lymphocyte Biology Unit, LPD, NIAID, NIH, Bethesda, Maryland 20892, USA. 4Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, NIAID, NIH, Bethesda, Maryland 20892, USA. 5Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA. 6Henan Chest Hospital, 450003 Zhengzhou, China. 7NIH, International Center for Excellence in Research, 600 031 Chennai, India. 8National Institute for Research in Tuberculosis (NIRT), 600 031 Chennai, India. 9Sino-US International Research Center for Tuberculosis, and Henan Public Health Center, 450003 Zhengzhou, China. 10Helminth Immunology Section, LPD, NIAID, NIH, Bethesda, Maryland 20892, USA. 11Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland 20892, USA. 12Oncovir Inc., Washington, Washington DC 20008, USA. |
publishDate |
2014 |
dc.date.issued.fl_str_mv |
2014 |
dc.date.accessioned.fl_str_mv |
2018-04-12T18:19:08Z |
dc.date.available.fl_str_mv |
2018-04-12T18:19:08Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
BARBER, K. D. M. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature, 2014 |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/25831 |
dc.identifier.issn.pt_BR.fl_str_mv |
0028-0836 |
dc.identifier.doi.none.fl_str_mv |
10.1038/nature13489 |
identifier_str_mv |
BARBER, K. D. M. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature, 2014 0028-0836 10.1038/nature13489 |
url |
https://www.arca.fiocruz.br/handle/icict/25831 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Nature Publishing Group |
publisher.none.fl_str_mv |
Nature Publishing Group |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/25831/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/25831/2/Barber%20KDM%20Host-directed....pdf https://www.arca.fiocruz.br/bitstream/icict/25831/3/Barber%20KDM%20Host-directed....pdf.txt |
bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 eb635d7b2a92a1081db2fea05b1a95da 19d7bad923c15f3a5dad7ab6af09e83b |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1813008844657262592 |